Open AccessSuccessful treatment of Listeria monocytogenes prosthetic valve endocarditis using rifampicin and benzylpenicillin in combination with valve replacement
Author(s) -
Tasnim Hasan,
W. Chik,
Sharon Chen,
Jen Kok
Publication year - 2017
Publication title -
jmm case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 5
ISSN - 2053-3721
DOI - 10.1099/jmmcr.0.005085
Subject(s) - rifampicin , medicine , listeria monocytogenes , endocarditis , osteomyelitis , discitis , vertebral osteomyelitis , surgery , microbiology and biotechnology , tuberculosis , pathology , biology , bacteria , radiology , magnetic resonance imaging , genetics
. Listeria monocytogenes is an uncommon cause of prosthetic valve endocarditis (PVE). Recommended antimicrobial therapy typically includes intravenous β-lactams with or without synergistic aminoglycosides. In vitro studies have previously identified antagonism when rifampicin has been used in combination with β-lactams. However, in vivo data of rifampicin use are limited despite its enhanced anti-biofilm activity. Case presentation. A 63-year-old male presented with fever and back pain. L. monocytogenes bacteraemia and bioprosthetic aortic valve endocarditis was confirmed, along with spinal discitis and osteomyelitis. He was successfully treated with benzylpenicillin and rifampicin, in conjunction with valve replacement. Conclusion. Rifampicin remains an alternate agent to use, when there are contraindications to traditional aminoglycoside therapy. Further data on rifampicin use in L. monocytogenes PVE are awaited.